Selective Serotonin Reuptake Inhibitors: Infrequent Medical Adverse Effects

Archives of Family Medicine

Volumn 7, Issue 1, 1998, Pages 78-84

  Goldberg, Richard J ^a,b  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

BLEEDING; CHEMICALLY INDUCED DISORDER; DIFFERENTIAL DIAGNOSIS; HEART ARRHYTHMIA; HUMAN; PHYSIOLOGY; REVIEW; SCHWARTZ BARTTER SYNDROME; SPINAL CORD DISEASE; SYNDROME;

ARRHYTHMIA; DIAGNOSIS, DIFFERENTIAL; HEMORRHAGE; HUMANS; INAPPROPRIATE ADH SYNDROME; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SPINAL CORD DISEASES; SYNDROME;

EID: 0031608375     PISSN: 10633987     EISSN: None     Source Type: Journal    
DOI: 10.1001/archfami.7.1.78     Document Type: Article

References (101)

1. Viswanath B, Navalgund AA, Cusano W, Navalgund KA. Fluoxetine as a cause of SIADH. Am J Psychiatry. 1991;148:542-543.
2. Blackstern J, Birt J. Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine. Ann Pharmacother. 1993;27:273-274.
3. Cohen B, Mahelsky M, Adler L. More cases of SIADH with fluoxetine. Am J Psychiatry. 1990;147:948-949.
4. Kazal L, Hall DL, Miller LG, et al. Fluoxetine-induced SIADH: a geriatric occurrence? J Fam Pract. 1993;36:341-343.
5. Hwang A, Magraw R. Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine. Am J Psychiatry. 1989;146:399.
6. Gommans J, Edwards R. Fluoxetine and hyponatremia. N Engl J Med. 1990; 307:103-106.
7. Jackson C, Carson W, Markowitz J, et al. SIADH associated with fluoxetine and sertraline therapy. Am J Psychiatry. 1995;152:809-810.
8. Goddard C, Patton C. Hyponatremia associated with paroxetine. BMJ. 1992; 305:1332.
9. Chua TP, Vong SK. Hyponatremia associated with paroxetine. BMJ. 1993;306:143.
10. Crews JR, Potts NL, Schreiber J, et al. Hyponatremia in a patient treated with sertraline. Am J Psychiatry. 1993;150:1564.
11. Thornton S, Resch D. SIADH associated with sertraline therapy. Am J Psychiatry. 1995;152:809.
12. Llorente M, Gorelick M, Silverman M. Sertraline as the cause of inappropriate antidiuretic hormone secretion. J Clin Psychiatry. 1994;22:543-544.
13. Uhde T, Post R. Effects of carbamazepine on serum electrolytes: clinical and theoretical implications. J Clin Psychopharmacol. 1983;3:103-106.
14. Sandifer M. Hyponatremia due to psychotropic drugs. J Clin Psychiatry. 1983; 44:301-303.
15. Luzecky M. The syndrome of inappropriate secretion of antidiuretic hormone associated with amitriptyline administration. South Med J. 1974;67:495-497.
16. Abbott R. Hyponatremia due to antidepressant medications. Ann Emerg Med. 1983;12:708-710.
17. Peterson JC, Pollak RW, Mahoney JJ, et al. Inappropriate antidiuretic hormone secondary to a monamine oxidase inhibitor. JAMA. 1978;239:1422-1423.
18. DeRivera J. Inappropriate secretion of antidiuretic hormone from fluphenazine therapy. Ann Intern Med. 1975;82:811-812.
19. Peck P, Shenkman L. Haloperidol-induced syndrome of inappropriate secre-tion of antidiuretic hormone. Clin Pharmacol Ther. 1979;26:442-444.
20. Kendler K, Weitzman R, Rubin R. Lack of argininevasopressin response to central dopamine blockade in normal adults. J Clin Endocrinol Metab. 1978;47:204-207.
21. MacMillan H, Gibson J, Steiner M. Hyponatremia and depression. J Nerv Ment Dis. 1990;178:720-722..
22. Zubenko GS, Altesman ṘI, Cassidy JW, et al. Disturbances of thirst and water homeostasis in patients with affective illness. Am J Psychiatry. 1984;141:436-437.
23. Kirmura T, Matsui K, Sato T, et al. Mechanism of carbamazepine (Tegretol) induced antidiuresis: evidence for release of antidiuretic hormone and impaired excretion of a water load. J Clin Endocrinol Metab. 1974;38:356-362.
24. Brownfield M, Greathouse J, Lorens S. Neuropharmacological characteization of serotoninergic stimulation of vasopressin secretion in conscious rats. Neuroendocrinology. 1988;47:277-283.
25. Hamburger S, Korprivica B, Ellerbeck E, et al. Thiazide-induced syndrome of inappropriate secretion of antidiuretic hormone: time course of resolution. JAMA. 1981;246:1235-1236.
26. Fichman M, Kleeman NC, Vorherr H. Diuretic-induced hyponatremia. Ann Intern Med. 1971;75:853-863.
27. Ashouri O. Severe diuretic-induced hyponatremia in the elderly. Arch Intern Med. 1986;146:1355-1357.
28. Dubovsky SL, Grabon S, Berl T, et al. Syndrome of inappropriate secretion of antidiuretic hormone with exacerbated psychosis. Am J Intern Med. 1973;79:551-554.
29. Raskind M, Orenstein H. Acute psychosis, increased water ingestion and inappropriate antidiuretic hormone secretion. Am J Psychiatry. 1975;132:907-910.
30. Coulter D, Pillans P. Fluoxetine and extrapyramidal side effects. Am J Psychiatry. 1995;152:122-125.
31. Arya D. Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br J Psychiatry. 1994;165:728-733.
32. Bouchard RH, Pourcher E, Fiteau MS, et al. Dose-related modulation of DA-dependent motor behavior by ritanserin (RIT) in idiopathic Parkinson's disease (PD). Neuropsychopharmacology. 1994;10(suppl):2105.
33. Meltzer H, Younger M, Metz J, et al. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm. 1979;45:165-175.
34. Choo V. Paroxetine and extrapyramidal reactions. Lancet. 1993;341:624.
35. Fisher S, Thomas KA, Stephen G, et al. Postmarketing surveillance by patient self-monitoring: preliminary data for sertraline versus fluoxetine. J Clin Psychiatry. 1995;56:288-296.
36. Committee on Safety of Medicine. Dystonia and withdrawal symptoms with paroxetine. Curr Probl Pharmacovigilance. 1993;19:1.
37. Guthrie S, Grunhaus L. Fluoxetine-induced stuttering. J Clin Psychiatry. 1990;51:85.
38. Friedman E. Fluoxetine and stuttering. J Clin Psychiatry. 1990;51:310.
39. McCall W. Sertraline-induced stuttering. J Clin Psychiatry. 1994;55:316.
40. Costa A, Kroll R. Sertaline in stuttering. J Clin Psychopharmacol. 1995;15:443-444.
41. Ellison J, Stanziani P. SSRI-associated nocturnal bruxism in four patients. J Clin Psychiatry. 1993;54:432-434.
42. McMillen BA, Matthews RT, Sanghera MK, et al. Dopamine receptor antagonism by the novel antianxiety drug, buspirone. J Neurosci. 1983;3:733-738.
43. Rothschild A, Locke CA. Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry. 1991;52:491-493.
44. Boyer W, Feighner J. Side effects of the selective serotonin reuptake inhibitors. In: Boyer W, Feighner J, eds. Selective Serotonin Reuptake Inhibitors. New York, NY: John Wiley & Sons; 1991:133-152.
45. Mendel J. Clinical experience with serotonin reuptake inhibiting antidepressants. J Clin Psychiatry. 1987;48:26-30.
46. Lipinski JF, Mallya G, Zimmerman P, et al. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry. 1989;50:339-342.
47. Wirshing W, Van Putten T, Rosenberg J, Marder S, Ames D, Hicks-Gray T. Fluoxetine, akathisia, and suicidality: is there a connection? Arch Gen Psychiatry. 1992; 49:580-581.
48. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153:466-476.
49. Hamilton M, Opler L. Akathisia, suicidality, and fluoxetine. J Clin Psychiatry. 1992;53:401-406.
50. Klee B, Kronig M. Case report of probable sertraline-induced akathisia. Am J Psychiatry. 1993;150:986-987.
51. Altshuler LL, Pierre JM, Wirshing WL, et al. Sertraline and akathisia. J Clin Psychopharmacol. 1994;14:278-279.
52. LaPorta L. Sertraline-induced akathisia. J Clin Psychopharmacol. 1993;13:219-220.
53. Settle E. Akathisia and sertraline. J Clin Psychiatry. 1993;54:321.
54. Dewey SI, Smith GS, Logan J, et al. Serotonergic modulation of striatal dopamine measued with positron emission tomography (PET) and in vivo microdialysis. J Neurosci. 1995;15:821-829.
55. Ceulemans DL, Gelders YG, Hoppenbrouwers ML, et al. Effect of serotonin antagonism in schizophrenia: a pilot study with steoperone. Psychopharmacology (Berl). 1985;85:329-332.
56. Ciraulo D, Shader R. Fluoxetine drug-drug interactions, I: antidepressants and antipsychotics. J Clin Psychopharmcol. 1990;10:48-50.
57. Goldberg R. The P-450 system: definition and relavance to the use of antidepressants in medical practice. Arch Fam Med. 1996; 5:406-411.
58. Shapiro P. Treatment of major depression after acute myocardial infarction with sertraline: a preliminary study. Presented at the annual meeting of the American Psychiatric Association; New York, NY; May 1, 1996.
59. Aranth J, Lindberg C. Bleeding, a side effect of fluoxetine. Am J Psychiatry. 1992; 149:412.
60. Yaryura-Tobias JA, Kirshen H, Ninan P, et al. Fluoxetine and bleeding in obsessive-compulsive disorder. Am J Psychiatry. 1991;148:949.
61. Artigas F, Sarris MJ, Martinez E, et al. Serotonin in body fluids: characterization of human and cerebrospinal, fluid pools by means of a new HPLC method. Life Sci. 1985;37:441-447.
62. Celada P, Dolera M, Alvqrez E, et al. Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients: relationships to clinical improvement. J Affect Disord. 1992;25:243-249.
63. Stahl S. Platelets as pharmacologic models for the receptors and biochemistry of monoaminergic neurons in the platelets. In: Longnecker GL, ed. Physiology and Pharmacology. Orlando, FIa: Academic Press; 1985:307-340.
64. Claire R, Servis M, Cram D. Potential interaction between warfarin sodium and fluoxetine. Am J Psychiatry. 1991;148:1604.
65. Goldstein J, deMorais S. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 1994;4:285-299.
66. Skop B, Brown T. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics. 1996;37:12-16.
67. Fisch C, Knoebel S. Electrocardiographs findings in sertraline depression trials. Drug Invest. 1992;4:305-312.
68. Warrington S. Clinical implications of the pharmacology of sertraline. Int Clin Psychopharmacol. 1991;6(suppl):11-21.
69. Edwards J, Goldie A, Papayanni-Papasthatis S. Effect of paroxetine on the electrocardiogram. Psychopharmacology. 1989;97:96-98.
70. Kuhs H, Rudolf G. Cardiovascular effects of paroxetine. Psychopharmacology. 1990;102:379-382.
71. Warrington S, Dana-Haeri J, Sinclair A. Cardiovascular and psychomotor effects of repeated doses of paroxetine: a comparison with amitriptyline and placebo in healthy men. Acta Psychiatr Scand. 1989;80(suppl):42-44.
72. Roose J. Cardiac effects of antidepressant drugs: a comparison of the tricyclic antidepressants and fluvoxamine. Br J Clin Pharmacol. 1983;15:4395-4455.
73. Fisch C. Effect of fluoxetine on the electrocardiogram. J Clin Psychiatry. 1985; 46:42-44.
74. Buff DD, Brenner R, Kirtane SS, et al. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psychiatry. 1991; 52:174-176.
75. Ellison J, Milofsky J, Ely E. Fluoxetine-induced bradycardia and syncope in two patients. J Clin Psychiatry. 1990;51:385-386.
76. Feder R. Bradycardia and syncope induced by fluoxetine. J Clin Psychiatry. 1991; 52:139.
77. Spier S, Frontera M. Unexpected death in depressed medical inpatients treated with fluoxetine. J Clin Psychiatry. 1991;52:377-382.
78. Hillis W, MacIntyre P. Sumatriptan and chest pain. Lancet. 1993;341:1564-1565.
79. Golino P, Piscione F, Benedict CR, et al. Local effect of serotonin released during coronary angioplasty. N Engl J Med. 1994;330:523-528.
80. Golino P, Piscione F, Willerson J. Divergent effects of serotonin on coronary artery dimensions and blood flow in patients with coronary athero-sclerosis and control patients. N Engl J Med. 1991:324:641-648.
81. McFadden EP, Clarke JG, Davies GJ, et al. Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Engl J Med. 1991;324:648-654.
82. Skop BP, Finklestein JA, Mareth TR, et al. The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease: a case report and review. Am J Emerg Med. 1994;12:642-644.
83. Gardner SF, Rutherford WF, Munger MA. Drug-induced supraventriculartachycardia: a case report of fluoxetine. Ann Emerg Med. 1991;120:194-197.
84. Drake W, Gordon G. Heart block in a patient on propranolol and fluoxetine. Lancet. 1994;343:425-426.
85. Walley T. Interaction of metoprolol and fluoxetine. Lancet. 1993;341:967-968.
86. Hayes L, Stewart C, Kim I, et al. Timolol side effects and inadvertent overdosing. J Am Geriatr Soc. 1989;37:261-262.
87. Ziegler M, Wilner K. Sertraline does not alterthe β-adrenergic blocking activity of atenolol in healthy male volunteers. J Clin Psychiatry. 1996;57(suppl):12-15.
88. Funck-Brentano C, Thomad G, Jacqz-Algrain E, et al. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. J Pharmacol Exp Ther. 1992;263:780.
89. Crewe H, Lennard M, Tucker G. The effect of selective serotonin uptake inhibitors on cytochrome P-4502D6 activity in human liver microsomes. Br J Clin Pharmacol. 1992;34:262-265.
90. Lee J, Kroemer H, Silberstein D, et al. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med. 1990;307:1764-1768.
91. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705-713.
92. Fischer P. Serotonin syndrome in the elderly after antidepressive mono-therapy. J Clin Psychopharmacol. 1995;15:440-442.
93. Kline SS, Mauro LS, Scala-Barnette DM, et al. Serotonin syndrome versus neruoleptic maligant syndrome as a cause of death. Clin Pharmacol. 1989;8:510-514.
94. Hansen T, Dieter K, Keepers G. Interaction of fluoxetine and pentazocine. Am J Psychiatry. 1990;147:949-950.
95. Feighner J, Boyer W, Tyler D. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry. 1990;51:222-225.
96. Sternbach H. Danger of MAOI therapy after fluoxetine withdrawal. Lancet. 1988; 2:850-851.
97. Steiner W, Fontaine R. Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports. Biol Psychiatry. 1986;21:1067-1071.
98. Bostwick JM, Brown TM. A toxic reaction from combining fluoxetine and phen-termine. J Ckin Psychopharmacol. 1996;16:189-190.
99. Goldberg R, Huk M. Serotonin syndrome from trazodone and buspirone. Psy-chosomatics. 1992;33:235-236.
100. Deakin J, Green A. The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats. Br J Pharmacol. 1978;64: 201-209.
101. Sprouse J, Aghajanian G. Propranolol blocks the inhibition of serotonergic dor-sal raphe cell fring by 5-HT1A selective agonists. Eur J Pharmacol. 1986;128: 295-298.